| Trial ID: | L0296 |
| Source ID: | NCT04972396
|
| Associated Drug: |
Metformin
|
| Title: |
ALT-801 DDI Study in Healthy Volunteers
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: ALT-801|Drug: Metformin|Drug: Atorvastatin|Drug: Warfarin|Drug: Digoxin|Drug: Ethinylestradiol and Levonorgestrel
|
| Outcome Measures: |
Area Under the Plasma Concentration Versus Time Curve (AUC) of metformin and atorvastatin/warfarin and digoxin in presence of steady state ALT-801|Area Under the Plasma Concentration Versus Time Curve (AUC) of ethinylestradiol and levonorgestrel in presence of steady state ALT-801|Cmax and Tmax of metformin and atorvastatin/warfarin and digoxin|Cmax and Tmax of ethinylestradiol and levonorgestrel|The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)
|
| Sponsor/Collaborators: |
Altimmune, Inc.
|
| Gender: |
All
|
| Age: |
18 Years to 55 Years ?? (Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
36
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other
|
| Start Date: |
October 5, 2021
|
| Completion Date: |
February 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
November 16, 2021
|
| Locations: |
Q-Pharm, Herston, Queensland, Australia|CMAX Clinical Research, Adelaide, South Australia, Australia
|
| URL: |
https://ClinicalTrials.gov/show/NCT04972396
|
